Dr. Patrick Soon-Shiong is Chairman & Chief Executive Officer Abraxis BioScience Inc. He is a noted research scientist—as well as a physician and surgeon—and has devoted his career to developing next-generation technology to enhance the medical care of patients with life-threatening diseases, including cancer, diabetes and heart disease. Dr. Soon-Shiong performed the world’s first encapsulated islet transplant in a diabetic patient and developed the nanoparticle delivery technology upon which the cremophor-free form of paclitaxel compound known as ABRAXANE® is based. The FDA approved ABRAXANE in January 2005 for treatment of advanced stage metastatic breast cancer and it is being developed for lung and melanoma cancers.
Dr. Soon-Shiong’s research has been recognized by noted organizations with numerous national and international awards such as the Association for Academic Surgery Award for Research, the American College of Surgeons Schering Scholar, the Royal College Physicians and Surgeons Research Award, the Peter Kiewit Distinguished Membership in Medicine Award, and the International J.W. Hyatt Award for Service to Mankind. He is a co-inventor of over 50 issued U.S. patents and has published more than 100 scientific papers.
Dr. Soon-Shiong currently serves on the Board of Directors for the National Institute of Transplantation as well as the Technology Council for the new Center for Cancer Nanotechnology Excellence at Northwestern University which is part of the National Cancer Institute’s (NCI) five-year initiative for nanotechnology in cancer research. He also serves on two advisory boards for the RAND Corporation, the RAND Center for Asia Pacific Policy and the RAND Health Board of Advisors.
Dr. Soon-Shiong holds a degree in Medicine from the University of the Witwatersrand, Johannesburg, South Africa, and a Master of Science from the University of British Columbia. He is a fellow of the American College of Surgeons and the Royal College of Physicians and Surgeons of Canada.